OncoMatch/Clinical Trials/NCT05896228
Iberdomide, Daratumumab, Carfilzomib, and Dexamethasone (Iber-KDd) in Patients With Relapsed/Refractory Multiple Myeloma
Is NCT05896228 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments for refractory multiple myeloma.
Treatment: Iberdomide · Carfilzomib · Daratumumab · Dexamethasone · Acetaminophen · Diphenhydramine · Montelukast — The investigators want to find out whether or not giving patients who have relapsed or refractory multiple myeloma (MM) the experimental medication combination iberdomide, carfilzomib, daratumumab, and dexamethasone (Iber-KDd) may produce better results than the current (standard of care) treatments. This study will examine the tolerability and efficacy of this combination therapy for all participants and the ability of this combination therapy to shrink or prevent MM from returning.
Check if I qualifyExtracted eligibility criteria
Cancer type
Multiple Myeloma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: lenalidomide-containing regimen (lenalidomide)
have received 1-3 lines of prior therapy (inclusive of a lenalidomide-containing regimen)
Cannot have received: iberdomide (iberdomide)
Prior treatment with iberdomide
Lab requirements
Blood counts
ANC ≥ 1.0 K cells/µL, hemoglobin ≥ 8 g/dL, and platelet count ≥ 50 K platelets/µL measured within 4 weeks of enrollment unless cytopenias are deemed to be due to disease
Kidney function
Creatinine Clearance (CrCl) ≥60 ml/min measured within 4 weeks of enrollment
Liver function
bilirubin < 1.5 x ULN and AST/ALT < 3.0 x ULN measured within 4 weeks of enrollment
Creatinine Clearance (CrCl) ≥60 ml/min... ANC ≥ 1.0 K cells/µL, hemoglobin ≥ 8 g/dL, and platelet count ≥ 50 K platelets/µL... Adequate hepatic function with bilirubin < 1.5 x ULN and AST/ALT < 3.0 x ULN
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of Miami · Miami, Florida
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify